The role of monoclonal antibody in the management of prostate adenocarcinoma.
A study using monoclonal antibody ProstaScint was conducted to determine the role of radioscintigraphy for evaluation of patients with adenocarcinoma of the prostate. Previous evaluations determining sensitivity and toxicity for this agent were conducted in a multicenter study. ProstaScint scans were used for preoperative staging in patients presumed to be candidates for total prostatectomy and a subsequent study was performed for the detection and localization of recurrent prostate cancer following definitive therapy. The monoclonal antibody scan detected localized recurrent cancer in 43 patients who were possible candidates for external beam radiation therapy. The monoclonal antibody conjugate ProstaScint provides additional information in detection and localization of recurrent prostate cancer and would be helpful in the selection of patients for subsequent external beam radiation therapy.